Group COO Joins the Clinigen Board
News Jul 15, 2013
Clinigen Group plc has announced the appointment of Shaun Edward Chilton (45) to the Board of Directors with effect from 11 July 2013.
Shaun Chilton has been employed by the Group since January 2012 as Chief Operating Officer and is a director of Clinigen CTS Limited and Clinigen CTS Inc., subsidiary companies of Clinigen Group plc.
He will now join the Board of Clinigen Group plc as an Executive Director.
Before joining Clinigen, he was the President within KnowledgePoint360 Group, a global pharmaceutical information and services operation.
He has over 20 years’ commercial, strategic and operational experience in senior leadership positions in product- and service-oriented businesses within the pharmaceutical industry.
He has a proven track record of creating and successfully driving business strategies delivering substantial sales, profit and market share growth in a number of international businesses; driving business transformation / change programmes and building, developing and coaching highly motivated, professional multidisciplinary teams.
Peter George, Group Chief Executive Officer said, “Since joining the Group in 2012 Shaun Chilton has been instrumental in driving the business forward, particularly in the CTS business which has grown substantially. His operational and strategic experience will be an asset to the Board as we continue to grow the business.”
Shaun holds 607,600 Ordinary Shares of 0.1 pence each in the Company (“Ordinary Shares”), representing 0.74% of the Company’s issued share capital.
He has share options over a further 412,778 Ordinary Shares, representing 0.5% of the Company’s issued share capital.
There is no further information required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.